FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200284047> ?p ?o ?g. }

• W4200284047 endingPage "S726" @default.
• W4200284047 startingPage "S725" @default.
• W4200284047 abstract "Abstract Background Ceftolozane/tazobactam (C/T), an antipseudomonal cephalosporin combined with a β-lactamase inhibitor, was approved for treatment of complicated urinary tract (cUTI) and intraabdominal infections (cIAI), and hospital-acquired/ventilator-associated bacterial pneumonia (HAP/VAP). Imipenem/relebactam (IMI/REL) is a combination of imipenem/cilastatin with relebactam, an inhibitor of class A and C β-lactamases. IMI/REL was approved for HAP/VAP and for infections due to aerobic gram-negative organisms in adults with limited treatment options (e.g., cUTI, cIAI). We compared the activity of C/T and IMI/REL against P. aeruginosa from bloodstream infections (BSI) to those from other infection types. Methods As part of the SMART program, 24 hospitals in the US and 8 in Canada each collected up to 250 consecutive gram-negative isolates per year in 2018-2019 from patients with BSI, lower respiratory tract infections (LRTI), IAI, and UTI. A total of 2351 Pa isolates were collected. MICs were determined using CLSI broth microdilution and breakpoints. Results Pa isolates from BSI tended to show higher susceptibility than IAI, UTI, and especially LRTI isolates (Table). Susceptibility to the tested comparator β-lactams was 11-12 percentage points lower among LRTI than BSI isolates, while C/T and IMI/REL susceptibility was only 2-5% lower. Even among BSI isolates, the comparator β-lactams were active against only 75-88% of isolates, while C/T and IMI/REL were active against &gt;95%. Only amikacin showed higher activity. Analyzing coverage by either C/T or IMI/REL, 98.7% of Pa isolates from BSI were susceptible to one or both agents. C/T and IMI/REL maintained activity against 89% and 69% of meropenem-nonsusceptible (MEM-NS) Pa isolates from BSI (n=36), respectively, and 87% and 76% of piperacillin/tazobactam (P/T)-NS Pa (n=38). Results Table Conclusion Even among BSI isolates, which were generally more susceptible than those from other infection types, Pa susceptibility to commonly used β-lactams like MEM and P/T was &lt; 90%, 7-23% lower than C/T and IMI/REL. Given the desirability of β-lactams among clinicians and the &gt;98% coverage by either C/T or IMI/REL of Pa isolates from BSI, both agents represent important options in the treatment of patients with BSI. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) C. Andrew DeRyke, PharmD, Merck & Co., Inc. (Employee, Shareholder) Kelly Harris, PharmD, BCPS, Merck & Co. Inc (Employee) Katherine Young, MS, Merck (Employee) Mary Motyl, PhD, Merck & Co., Inc. (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
• W4200284047 created "2021-12-31" @default.
• W4200284047 creator A5010520517 @default.
• W4200284047 creator A5017159626 @default.
• W4200284047 creator A5037643218 @default.
• W4200284047 creator A5038009031 @default.
• W4200284047 creator A5042149117 @default.
• W4200284047 creator A5062847775 @default.
• W4200284047 creator A5089366807 @default.
• W4200284047 date "2021-11-01" @default.
• W4200284047 modified "2023-09-27" @default.
• W4200284047 title "1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against Pseudomonas aeruginosa Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019" @default.
• W4200284047 doi "https://doi.org/10.1093/ofid/ofab466.1466" @default.
• W4200284047 hasPublicationYear "2021" @default.
• W4200284047 type Work @default.
• W4200284047 citedByCount "0" @default.
• W4200284047 crossrefType "journal-article" @default.
• W4200284047 hasAuthorship W4200284047A5010520517 @default.
• W4200284047 hasAuthorship W4200284047A5017159626 @default.
• W4200284047 hasAuthorship W4200284047A5037643218 @default.
• W4200284047 hasAuthorship W4200284047A5038009031 @default.
• W4200284047 hasAuthorship W4200284047A5042149117 @default.
• W4200284047 hasAuthorship W4200284047A5062847775 @default.
• W4200284047 hasAuthorship W4200284047A5089366807 @default.
• W4200284047 hasBestOaLocation W42002840471 @default.
• W4200284047 hasConcept C126322002 @default.
• W4200284047 hasConcept C176947019 @default.
• W4200284047 hasConcept C2776685102 @default.
• W4200284047 hasConcept C2777050379 @default.
• W4200284047 hasConcept C2777427914 @default.
• W4200284047 hasConcept C2777637488 @default.
• W4200284047 hasConcept C2778266534 @default.
• W4200284047 hasConcept C2779375183 @default.
• W4200284047 hasConcept C2779631663 @default.
• W4200284047 hasConcept C2780950330 @default.
• W4200284047 hasConcept C501593827 @default.
• W4200284047 hasConcept C523546767 @default.
• W4200284047 hasConcept C54355233 @default.
• W4200284047 hasConcept C71924100 @default.
• W4200284047 hasConcept C86803240 @default.
• W4200284047 hasConcept C89423630 @default.
• W4200284047 hasConcept C94665300 @default.
• W4200284047 hasConceptScore W4200284047C126322002 @default.
• W4200284047 hasConceptScore W4200284047C176947019 @default.
• W4200284047 hasConceptScore W4200284047C2776685102 @default.
• W4200284047 hasConceptScore W4200284047C2777050379 @default.
• W4200284047 hasConceptScore W4200284047C2777427914 @default.
• W4200284047 hasConceptScore W4200284047C2777637488 @default.
• W4200284047 hasConceptScore W4200284047C2778266534 @default.
• W4200284047 hasConceptScore W4200284047C2779375183 @default.
• W4200284047 hasConceptScore W4200284047C2779631663 @default.
• W4200284047 hasConceptScore W4200284047C2780950330 @default.
• W4200284047 hasConceptScore W4200284047C501593827 @default.
• W4200284047 hasConceptScore W4200284047C523546767 @default.
• W4200284047 hasConceptScore W4200284047C54355233 @default.
• W4200284047 hasConceptScore W4200284047C71924100 @default.
• W4200284047 hasConceptScore W4200284047C86803240 @default.
• W4200284047 hasConceptScore W4200284047C89423630 @default.
• W4200284047 hasConceptScore W4200284047C94665300 @default.
• W4200284047 hasIssue "Supplement_1" @default.
• W4200284047 hasLocation W42002840471 @default.
• W4200284047 hasLocation W42002840472 @default.
• W4200284047 hasOpenAccess W4200284047 @default.
• W4200284047 hasPrimaryLocation W42002840471 @default.
• W4200284047 hasRelatedWork W2622511718 @default.
• W4200284047 hasRelatedWork W2751398372 @default.
• W4200284047 hasRelatedWork W2981473355 @default.
• W4200284047 hasRelatedWork W3196287570 @default.
• W4200284047 hasRelatedWork W4200284047 @default.
• W4200284047 hasRelatedWork W4213268551 @default.
• W4200284047 hasRelatedWork W4288069133 @default.
• W4200284047 hasRelatedWork W4309754201 @default.
• W4200284047 hasRelatedWork W4313420392 @default.
• W4200284047 hasRelatedWork W4313830871 @default.
• W4200284047 hasVolume "8" @default.
• W4200284047 isParatext "false" @default.
• W4200284047 isRetracted "false" @default.
• W4200284047 workType "article" @default.